Hofseth BioCare ASA (HBC.OL)
NOK 1.95
(0.0%)
NOK 1.95
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -102.52 Million NOK | 1.91% |
| 2022 | -128.61 Million NOK | -8.48% |
| 2021 | -118.56 Million NOK | -28.85% |
| 2020 | -92.02 Million NOK | -15.64% |
| 2019 | -79.57 Million NOK | -2.41% |
| 2018 | -77.69 Million NOK | -593.99% |
| 2017 | -11.19 Million NOK | 92.26% |
| 2016 | -144.56 Million NOK | -54.87% |
| 2015 | -93.34 Million NOK | -47.66% |
| 2014 | -63.21 Million NOK | -33.12% |
| 2013 | -47.48 Million NOK | 18.19% |
| 2012 | -58.04 Million NOK | -138.68% |
| 2011 | -24.31 Million NOK | -88.45% |
| 2010 | -12.9 Million NOK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -19.78 Million NOK | 55.86% |
| 2024 Q1 | -26.2 Million NOK | 46.82% |
| 2023 Q2 | 8.37 Million NOK | 122.98% |
| 2023 Q4 | -49.28 Million NOK | -138.92% |
| 2023 Q3 | -20.62 Million NOK | -346.22% |
| 2023 FY | -126.16 Million NOK | 1.91% |
| 2023 Q1 | -36.46 Million NOK | -3.43% |
| 2022 Q4 | -35.25 Million NOK | -6.46% |
| 2022 Q3 | -33.11 Million NOK | -23.61% |
| 2022 Q2 | -26.78 Million NOK | 19.96% |
| 2022 FY | -128.61 Million NOK | -8.48% |
| 2022 Q1 | -33.46 Million NOK | 1.58% |
| 2021 Q2 | -22.77 Million NOK | 9.03% |
| 2021 Q1 | -25.03 Million NOK | 13.84% |
| 2021 Q3 | -36.75 Million NOK | -61.4% |
| 2021 Q4 | -34 Million NOK | 7.47% |
| 2021 FY | -118.56 Million NOK | -28.85% |
| 2020 FY | -92.02 Million NOK | -15.64% |
| 2020 Q1 | -15.98 Million NOK | 48.77% |
| 2020 Q3 | -29.16 Million NOK | -63.65% |
| 2020 Q2 | -17.81 Million NOK | -11.45% |
| 2020 Q4 | -29.05 Million NOK | 0.37% |
| 2019 Q4 | -31.21 Million NOK | -117.04% |
| 2019 Q2 | -14.67 Million NOK | 24.0% |
| 2019 Q1 | -19.3 Million NOK | -3.81% |
| 2019 Q3 | -14.38 Million NOK | 1.99% |
| 2019 FY | -79.57 Million NOK | -2.41% |
| 2018 Q2 | -18.26 Million NOK | 11.3% |
| 2018 FY | -77.69 Million NOK | -593.99% |
| 2018 Q1 | -20.59 Million NOK | -73.98% |
| 2018 Q4 | -18.59 Million NOK | 8.1% |
| 2018 Q3 | -20.23 Million NOK | -10.77% |
| 2017 Q3 | -11.34 Million NOK | 38.41% |
| 2017 FY | -11.19 Million NOK | 92.26% |
| 2017 Q4 | -11.83 Million NOK | -4.4% |
| 2017 Q1 | 30.39 Million NOK | 217.12% |
| 2017 Q2 | -18.41 Million NOK | -160.58% |
| 2016 Q4 | -25.95 Million NOK | 43.09% |
| 2016 FY | -144.56 Million NOK | -54.87% |
| 2016 Q2 | -47.46 Million NOK | -85.78% |
| 2016 Q1 | -25.54 Million NOK | 35.97% |
| 2016 Q3 | -45.6 Million NOK | 3.91% |
| 2015 Q3 | -15.73 Million NOK | 17.73% |
| 2015 Q4 | -39.89 Million NOK | -153.65% |
| 2015 FY | -93.34 Million NOK | -47.66% |
| 2015 Q1 | -18.59 Million NOK | 34.04% |
| 2015 Q2 | -19.12 Million NOK | -2.82% |
| 2014 FY | -63.21 Million NOK | -33.12% |
| 2014 Q4 | -28.19 Million NOK | -102.95% |
| 2014 Q3 | -13.89 Million NOK | -46.38% |
| 2014 Q2 | -9.49 Million NOK | 18.5% |
| 2014 Q1 | -11.64 Million NOK | -3.41% |
| 2013 Q1 | -15.5 Million NOK | 29.54% |
| 2013 Q2 | -13.84 Million NOK | 10.69% |
| 2013 Q3 | -6.87 Million NOK | 50.36% |
| 2013 Q4 | -11.26 Million NOK | -63.81% |
| 2013 FY | -47.48 Million NOK | 18.19% |
| 2012 Q1 | -15.54 Million NOK | -111.71% |
| 2012 Q3 | -8.43 Million NOK | 30.02% |
| 2012 Q4 | -22 Million NOK | -160.87% |
| 2012 FY | -58.04 Million NOK | -138.68% |
| 2012 Q2 | -12.05 Million NOK | 22.47% |
| 2011 Q1 | -5.54 Million NOK | 28.63% |
| 2011 Q4 | -7.34 Million NOK | -21.64% |
| 2011 FY | -24.31 Million NOK | -88.45% |
| 2011 Q3 | -6.03 Million NOK | -11.88% |
| 2011 Q2 | -5.39 Million NOK | 2.64% |
| 2010 Q4 | -7.76 Million NOK | -471.15% |
| 2010 FY | -12.9 Million NOK | 0.0% |
| 2010 Q3 | -1.35 Million NOK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Arctic Bioscience AS | -48.58 Million NOK | -111.025% |
| Aqua Bio Technology ASA | -17.85 Million NOK | -474.162% |
| ArcticZymes Technologies ASA | 15.74 Million NOK | 751.143% |
| BerGenBio ASA | -191.81 Million NOK | 46.549% |
| PCI Biotech Holding ASA | -22.24 Million NOK | -360.991% |
| Thor Medical ASA | -7.16 Million NOK | -1331.969% |
| Ultimovacs ASA | -215.73 Million NOK | 52.475% |